Base editing with nuclease flexibility

The Pin-point™ platform features a novel three-part design that offers the flexibility to "mix and match" individual system components, allowing optimization of each targeted gene edit.

In this application note, we demonstrate this flexibility by exchanging nCas9 for the deactivated Type V protein dCasMINI, a modified version of Un1Cas12f1 optimized for enhanced activity and with a low off-target profile.

You will learn about…

• The flexibility and modular nature of the Pin-point base editing platform
• How its modularity allows for the customization of its three components to be optimized to the target site
• Detailed data and analysis from testing of the flexibility and modularity of the platform

The Pin-point platform technology is available for clinical study and commercialization under a commercial license from Revvity. Pin-point reagents are available for research use only.